Peptides: Tirzepatide — Dual GIP + GLP-1 Receptor Agonist
Jastreboff 2022 (PMID 35658024): tirzepatide 15mg/week × 72 weeks achieved 22.5% mean body weight loss; 96% achieved ≥5% and 63% achieved ≥20% weight loss threshold.
| Measure | Value | Unit | Notes |
|---|---|---|---|
| Evidence Grade | A | grade | Multiple large Phase 3 RCTs (SURMOUNT-1 to 4, SURPASS-1 to 6); FDA-approved for T2D (Mounjaro 2022) and obesity (Zepbound 2023) |
| Mean Weight Loss (15mg) | 22.5 | % body weight | SURMOUNT-1 (PMID 35658024): 72 weeks; vs 2.5% placebo; highest effect in obesity trial to date |
| vs Semaglutide Advantage | ~7.6 | % additional weight loss | SURMOUNT-1 15mg: 22.5% vs semaglutide STEP 1: 14.9%; head-to-head in SURPASS-2 also favored tirzepatide |
| Half-Life | ~5 | days | Enables once-weekly dosing; C18 fatty acid modification enables albumin binding similar to semaglutide |
| Peptide Length | 39 | amino acids | 39-aa synthetic peptide based on GIP sequence with GLP-1R agonist modifications; single molecule hits both receptors |
| Receptor Targets | 2 | receptors | Glucose-dependent insulinotropic polypeptide receptor (GIPR) and GLP-1 receptor (GLP-1R); balanced agonism at both |
| ≥20% Weight Loss Responders | 63 | % at 15mg | SURMOUNT-1: 63% of participants on 15mg achieved ≥20% body weight loss — unprecedented in large RCT |
Why Tirzepatide Represents a Peptide Engineering Milestone
Tirzepatide is a 39 amino acid synthetic peptide engineered to be a balanced agonist at two distinct receptor systems: the GIP receptor (GIPR) and the GLP-1 receptor (GLP-1R). This dual-agonist design is a significant advance over first-generation incretin mimetics (GLP-1R agonists only) and represents the current ceiling of approved pharmacological weight loss — 22.5% mean body weight reduction at the highest dose in the SURMOUNT-1 trial.
Understanding tirzepatide’s mechanism clarifies how peptide drug design iterates toward greater efficacy: each generation learns what the previous one missed and engineers new receptor targets into the same backbone.
The Dual Incretin System
Two incretins control the post-meal insulin response in humans:
- GLP-1 (glucagon-like peptide-1): Secreted by intestinal L-cells; acts on pancreatic beta cells (insulin secretion), hypothalamus (satiety), and vagal nerve. Half-life: ~2 minutes endogenously.
- GIP (glucose-dependent insulinotropic polypeptide): Secreted by intestinal K-cells; acts on pancreatic beta cells, adipocytes (lipid metabolism), and possibly hypothalamus. Half-life: ~7 minutes endogenously.
Semaglutide targets only GLP-1R. Tirzepatide targets both. The GIP receptor contribution appears to add adipocyte-level lipolysis signaling and a second pathway of insulin amplification that GLP-1R agonism alone cannot produce. The result is greater metabolic remodeling per weekly dose.
Efficacy Comparison Table
| Compound | Receptor Targets | Half-Life | Mean Weight Loss | ≥20% Responders | Evidence Grade | Status |
|---|---|---|---|---|---|---|
| Endogenous GLP-1/GIP | GLP-1R + GIPR (natural) | ~2–7 min | N/A | N/A | A (reference) | Endogenous |
| Liraglutide 3mg | GLP-1R | ~13 hours | 5–6% (SCALE) | ~12% | A | FDA Rx |
| Semaglutide 2.4mg | GLP-1R | ~7 days | 14.9% (STEP 1) | ~32% | A | FDA Rx |
| Tirzepatide 5mg | GLP-1R + GIPR | ~5 days | 15.0% (SURMOUNT-1) | ~27% | A | FDA Rx |
| Tirzepatide 10mg | GLP-1R + GIPR | ~5 days | 19.5% (SURMOUNT-1) | ~49% | A | FDA Rx |
| Tirzepatide 15mg | GLP-1R + GIPR | ~5 days | 22.5% (SURMOUNT-1) | ~63% | A | FDA Rx |
| Retatrutide (Phase 3) | GLP-1R + GIPR + GcgR | ~6 days | ~24.2% (Phase 2) | N/A | B (Phase 2) | Investigational |
The progression from single to dual to triple receptor agonism (GLP-1R + GIPR + glucagon receptor, as in retatrutide) continues in Phase 3 trials. Each added receptor target has increased mean weight loss by approximately 5–8 percentage points.
Structural Design
Tirzepatide is a 39 amino acid peptide based on the native GIP sequence, with strategic amino acid substitutions to enable GLP-1R binding. Key engineering features:
- GIP scaffold: native GIP(1-42) truncated and modified for improved receptor binding
- GLP-1R agonism: substitutions at positions 2, 13, and 20 confer GLP-1R activity without losing GIPR activity
- Fatty acid linker: C18 fatty diacid via gamma-glutamic acid spacer at position 20 — enables albumin binding and ~5-day half-life
- Balanced agonism: approximately equimolar potency at both receptors — not a GLP-1R biased molecule
Legal and Regulatory Status
| Jurisdiction | Status | Common Names | Notes |
|---|---|---|---|
| USA | Prescription only | Mounjaro (T2D), Zepbound (obesity) | FDA-approved 2022 (T2D) and 2023 (obesity); controlled shortage post-launch |
| UK | Prescription only | Mounjaro | MHRA-approved; NHS coverage for obesity in staged rollout |
| Australia | Schedule 4 | Mounjaro | TGA-approved; Zepbound pending as of 2024 |
| Canada | Prescription only | Mounjaro | Health Canada approved for T2D; obesity indication filing in progress |
| EU | Prescription only | Mounjaro | EMA-approved 2022 (T2D); obesity approval 2024 |
Evidence Grade
Grade A — Tirzepatide is supported by multiple large Phase 3 RCTs (SURMOUNT-1 through SURMOUNT-4 for obesity; SURPASS-1 through SURPASS-6 for T2D) with tens of thousands of participants, regulatory review by FDA and EMA, and long-term cardiovascular outcome trial data in progress (SURPASS-CVOT). No higher evidence level exists in clinical pharmacology.
Legal Disclaimer
Tirzepatide is a prescription pharmaceutical, not a research chemical. Any use of tirzepatide requires a valid prescription from a licensed prescribing clinician. Off-label or unsupervised use carries risks including GI adverse events, potential thyroid C-cell effects (noted in rodent studies; not confirmed in humans), pancreatitis risk, and drug interactions. The content on this page is educational and does not constitute medical advice.
Related Pages
Sources
- Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. PMID 35658024
- Frias JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503-515. PMID 34170647
- Coskun T et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. Mol Metab. 2018;18:3-14. PMID 30287102
Frequently Asked Questions
How does tirzepatide achieve more weight loss than semaglutide?
Tirzepatide activates both the GIP receptor (GIPR) and the GLP-1 receptor (GLP-1R) simultaneously, whereas semaglutide is a selective GLP-1R agonist. GIP receptor agonism adds additional metabolic effects: enhanced insulin secretion from a second incretin pathway, direct adipocyte lipolysis signaling, and possible synergistic central appetite regulation. The combined dual-receptor activation appears to produce additive and possibly synergistic weight loss — SURMOUNT-1 showed 22.5% mean weight loss at 15mg vs approximately 14.9% for semaglutide in a separate but contemporaneous trial.
What is the SURMOUNT-1 trial?
SURMOUNT-1 (Jastreboff et al. 2022, PMID 35658024) was a Phase 3 RCT enrolling 2,519 adults with obesity (BMI ≥30 or ≥27 with comorbidity) and without diabetes. Participants were randomized to tirzepatide 5mg, 10mg, or 15mg once weekly or placebo for 72 weeks, all with lifestyle counseling. Mean weight loss: 15.0% (5mg), 19.5% (10mg), 22.5% (15mg) vs 2.5% placebo. This was the largest mean weight loss effect size ever reported in a Phase 3 obesity pharmacotherapy trial.
What are GIP and GLP-1?
Both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) are incretins — gut-derived hormones released after food ingestion that coordinate the insulin response. GLP-1 is produced in intestinal L-cells and acts on the hypothalamus, pancreatic beta cells, and vagal nerve. GIP is produced in intestinal K-cells and acts primarily on pancreatic beta cells and adipocytes. Endogenous half-lives of both are approximately 2 minutes; tirzepatide extends this to ~5 days via a fatty acid albumin-binding modification.
Is tirzepatide approved for weight loss?
Yes. Tirzepatide was approved by the FDA as Mounjaro in 2022 for Type 2 diabetes (2.5–15mg/week dose escalation). In November 2023, the FDA approved it as Zepbound specifically for chronic weight management in adults with BMI ≥30, or ≥27 with at least one weight-related comorbidity. The EMA approved it in Europe for obesity in 2024. Prescription access varies by jurisdiction.